Cat. No. | Product name | CAS No. |
DCC4880 |
Srebp-in-dhg
Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK) |
|
DCC4881 |
Sri-22138
Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist |
|
DCC4882 |
Sri-29132
Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons. |
1482305-44-1 |
DCC4883 |
Sri-31040
Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding |
1928715-72-3 |
DCC4884 |
Sri-35241
Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv) |
2307429-54-3 |
DCC4885 |
Sri-36160
Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells |
2085682-66-0 |
DCC4886 |
Sri-37683
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
DCC4887 |
Sri-37684
Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri |
|
DCC4888 |
Sri-39067
Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice |
|
DCC4889 |
Srt3025
Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss |
1231952-55-8 |
DCC4890 |
Srt3025 Hydrochloride
Novel potent SIRT1 activator |
2070015-26-6 |
DCC4891 |
Srt3190 (2s,3r)
Novel selective CXCR2 antagonist |
1204707-73-2 |
DCC4892 |
Srta-in-i
Novel potent inhibitor of Staphylococcus aureus sortase A (SrtA) |
|
DCC4893 |
Ss1020
Novel antiestrogen, lacking estrogenic and genotoxic actions |
|
DCC4894 |
SS-amyloid-in-7l
Potent ß-amyloid aggregation inhibitor; Antioxidant |
|
DCC4895 |
SS-carboline-1-carboxylic Acid
Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO) |
26052-96-0 |
DCC4896 |
SS-cit
Non-selective potent dopamine reuptake inhibitor |
135416-43-2 |
DCC4897 |
SS-cit Tartrate
Non-selective potent dopamine reuptake inhibitor |
133647-95-7 |
DCC4898 |
SS-elemene
Novel inhibitor of Pak1 activation, anti-cancer ingredient isolated from the Chinese traditional herb Curcuma wenyujin |
33880-83-0 |
DCC4899 |
SS-hydroxymethyl Chalcone
The first selective inhibitor of Histone Deacetylase 2 (HDAC2) |
1613310-15-8 |
DCC4900 |
Ssj-183
Novel antimalarial agent |
1187533-34-1 |
DCC4901 |
SS-lysine
Elongation factor P (EF-P) fuction modifier |
4299-56-3 |